MedTrace Logo

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

NCT06454188 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-04-03

No results posted yet for this study

Summary

A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)

Conditions

Interventions

DRUG

Upadacitinib 15 MG [Rinvoq]

15mg tablet once per day.

DRUG

Placebo

15mg tablet once per day.

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • CARE ARTHRITIS LTD.

    lead INDUSTRY

Principal Investigators

  • Walter Maksymowych, Dr. · CARE ARTHRITIS LTD.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-03
Primary Completion
2028-09-30
Completion
2028-10-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06454188 on ClinicalTrials.gov